Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MindBio Therapeutics Corp. is making strides in mental health with Dr. Rachael Sumner presenting groundbreaking women’s health trials, aiming to treat PMS and PMDD more effectively with fewer side effects. The company is advancing with multiple Phase 2B trials using MB22001, a self-administered microdosing form of LSD, and is set to release promising secondary data from a Phase 2A depression trial that has already shown significant symptom reduction.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.